A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

Maja de Jonge, VA de Weger, MA Dickson, M Langenberg, A le Cesne, AJ Wagner, K Hsu, W Zheng, S Mace, G Tuffal, K Thomas, JHM Schellens

Research output: Contribution to journalArticleAcademicpeer-review

93 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)144-151
Number of pages8
JournalEuropean Journal of Cancer
Publication statusPublished - 2017

Research programs

  • EMC MM-03-86-08

Cite this